Covid-19 Research

Clinical Trials

Gut Microbiota, Cardiovascular Innovation, and Lifestyle Medicine: Southeast Asia’s First Clinical Integration of TMAO Testing

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Clinical Trials
Subject Medicine Group
OCLC JBRES Record
Ali Usman*
Issue: Volume6-Issue6
Pages: 646-651
Received: 2025-05-07
Accepted: 2025-06-13
Published: 2025-06-14

Abstract

Trimethylamine N-Oxide (TMAO) has emerged as a novel biomarker implicated in the pathogenesis and progression of various cardiometabolic conditions, including Coronary Artery Disease (CAD), stroke, type 2 diabetes mellitus, obesity/metabolic syndrome, chronic kidney disease, restenosis, and heart failure. Despite increasing global recognition of its clinical relevance, TMAO testing was not available in Indonesia until Bethsaida Hospital, under the leadership of Prof. Dasaad Mulijono, successfully established a partnership with Prodia, the only private laboratory in the country willing to invest in TMAO diagnostic technology.

This article describes the implementation of TMAO testing at Bethsaida Hospital, evaluates its diagnostic and prognostic utility, and explores its role in monitoring adherence to a healthy Plant-Based Diet (PBD).

Bethsaida Hospital is also a national pioneer in using Drug-Coated Balloon (DCB) technology for coronary interventions. Ongoing research at the institution investigates the relationship between TMAO levels and dietary adherence among cardiac patients. Individuals with lower TMAO concentrations tend to exhibit a reduced restenosis rate following DCB procedures. Furthermore, patients who demonstrate regression of coronary plaques, particularly those adhering to a PBD, consistently exhibit low TMAO levels, supporting its potential as a surrogate marker for a favourable gut microbiota composition and dietary pattern.

TMAO remains the only clinically available biomarker that indirectly reflects gut microbiota health concerning dietary intake, particularly in individuals following a PBD. Its potential application in precision medicine holds promise for enhancing risk stratification, guiding therapeutic interventions, and improving long-term cardiovascular outcomes in patients with cardiometabolic disorders.

FullText HTML FullText PDF DOI: 10.37871/jbres2118 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2025 Usman A, Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Usman A. Gut Microbiota, Cardiovascular Innovation, and Lifestyle Medicine: Southeast Asia’s First Clinical Integration of TMAO Testing. J Biomed Res Environ Sci. 2025 Jun 14; 6(6): 646-651. doi: 10.37871/jbres2118, Article ID: JBRES2118, Available at: https://www.jelsciences.com/articles/jbres2118.pdf

Subject area(s)

Clinical TrialsNutritionCardiovascular Diseases

References

  1. Di Cesare M, Perel P, Taylor S, Kabudula C, Bixby H, Gaziano TA, McGhie DV, Mwangi J, Pervan B, Narula J, Pineiro D, Pinto FJ. The Heart of the World. Glob Heart. 2024 Jan 25;19(1):11. doi: 10.5334/gh.1288. PMID: 38273998; PMCID: PMC10809869.
  2. Gaidai O, Cao Y, Loginov S. Global Cardiovascular Diseases Death Rate Prediction. Curr Probl Cardiol. 2023 May;48(5):101622. doi: 10.1016/j.cpcardiol.2023.101622. Epub 2023 Jan 29. PMID: 36724816.
  3. Chong B, Jayabaskaran J, Jauhari SM, Chan SP, Goh R, Kueh MTW, Li H, Chin YH, Kong G, Anand VV, Wang JW, Muthiah M, Jain V, Mehta A, Lim SL, Foo R, Figtree GA, Nicholls SJ, Mamas MA, Januzzi JL, Chew NWS, Richards AM, Chan MY. Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur J Prev Cardiol. 2024 Sep 13:zwae281. doi: 10.1093/eurjpc/zwae281. Epub ahead of print. PMID: 39270739.
  4. Muharram FR, Multazam CECZ, Mustofa A, Socha W, Andrianto, Martini S, Aminde L, Yi-Li C. The 30 Years of Shifting in The Indonesian Cardiovascular Burden-Analysis of The Global Burden of Disease Study. J Epidemiol Glob Health. 2024 Mar;14(1):193-212. doi: 10.1007/s44197-024-00187-8. Epub 2024 Feb 7. Erratum in: J Epidemiol Glob Health. 2024 Sep;14(3):1369. doi: 10.1007/s44197-024-00280-y. PMID: 38324147; PMCID: PMC11043320.
  5. Harmadha WSP, Muharram FR, Gaspar RS, Azimuth Z, Sulistya HA, Firmansyah F, Multazam CECZ, Harits M, Putra RM. Explaining the increase of incidence and mortality from cardiovascular disease in Indonesia: A global burden of disease study analysis (2000-2019). PLoS One. 2023 Dec 15;18(12):e0294128. doi: 10.1371/journal.pone.0294128. PMID: 38100501; PMCID: PMC10723707.
  6. Amrein M, Li XS, Walter J, Wang Z, Zimmermann T, Strebel I, Honegger U, Leu K, Schäfer I, Twerenbold R, Puelacher C, Glarner N, Nestelberger T, Koechlin L, Ceresa B, Haaf P, Bakula A, Zellweger M, Hazen SL, Mueller C. Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD). Clin Res Cardiol. 2022 Jun;111(6):692-704. doi: 10.1007/s00392-022-01992-6. Epub 2022 Feb 26. PMID: 35220448; PMCID: PMC9151506.
  7. Zhou X, Jin M, Liu L, Yu Z, Lu X, Zhang H. Trimethylamine N-oxide and cardiovascular outcomes in patients with chronic heart failure after myocardial infarction. ESC Heart Fail. 2020 Feb;7(1):188-193. doi: 10.1002/ehf2.12552. Epub 2020 Jan 20. PMID: 31960610; PMCID: PMC7083407.
  8. Guasti L, Galliazzo S, Molaro M, Visconti E, Pennella B, Gaudio GV, Lupi A, Grandi AM, Squizzato A. TMAO as a biomarker of cardiovascular events: a systematic review and meta-analysis. Intern Emerg Med. 2021 Jan;16(1):201-207. doi: 10.1007/s11739-020-02470-5. Epub 2020 Aug 10. PMID: 32779113.
  9. Chen G, He L, Dou X, Liu T. Association of Trimethylamine-N-Oxide Levels with Risk of Cardiovascular Disease and Mortality among Elderly Subjects: A Systematic Review and Meta-Analysis. Cardiorenal Med. 2022;12(2):39-54. doi: 10.1159/000520910. Epub 2021 Dec 16. PMID: 34915483.
  10. Canyelles M, Borràs C, Rotllan N, Tondo M, Escolà-Gil JC, Blanco-Vaca F. Gut Microbiota-Derived TMAO: A Causal Factor Promoting Atherosclerotic Cardiovascular Disease? Int J Mol Sci. 2023 Jan 18;24(3):1940. doi: 10.3390/ijms24031940. PMID: 36768264; PMCID: PMC9916030.
  11. Xie G, Yan A, Lin P, Wang Y, Guo L. Trimethylamine N-oxide-a marker for atherosclerotic vascular disease. Rev Cardiovasc Med. 2021 Sep 24;22(3):787-797. doi: 10.31083/j.rcm2203085. PMID: 34565077.
  12. Lee Y, Nemet I, Wang Z, Lai HTM, de Oliveira Otto MC, Lemaitre RN, Fretts AM, Sotoodehnia N, Budoff M, DiDonato JA, McKnight B, Tang WHW, Psaty BM, Siscovick DS, Hazen SL, Mozaffarian D. Longitudinal Plasma Measures of Trimethylamine N-Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community-Based Older Adults. J Am Heart Assoc. 2021 Sep 7;10(17):e020646. doi: 10.1161/JAHA.120.020646. Epub 2021 Aug 16. PMID: 34398665; PMCID: PMC8649305.
  13. Wang B, Qiu J, Lian J, Yang X, Zhou J. Gut Metabolite Trimethylamine-N-Oxide in Atherosclerosis: From Mechanism to Therapy. Front Cardiovasc Med. 2021 Nov 23;8:723886. doi: 10.3389/fcvm.2021.723886. PMID: 34888358; PMCID: PMC8650703.
  14. Wang M, Li XS, Wang Z, de Oliveira Otto MC, Lemaitre RN, Fretts A, Sotoodehnia N, Budoff M, Nemet I, DiDonato JA, Tang WHW, Psaty BM, Siscovick DS, Hazen SL, Mozaffarian D. Trimethylamine N-oxide is associated with long-term mortality risk: the multi-ethnic study of atherosclerosis. Eur Heart J. 2023 May 7;44(18):1608-1618. doi: 10.1093/eurheartj/ehad089. PMID: 36883587; PMCID: PMC10411925.
  15. Spasova N, Somleva D, Krastev B, Ilieva R, Borizanova A, Svinarov D, Kinova E, Goudev A. Association of the trimethylamine N-oxide with cardiovascular risk and vascular alterations in middle-aged patients with risk factors for cardiovascular diseases. Biosci Rep. 2024 Apr 29;44(5):BSR20232090. doi: 10.1042/BSR20232090. PMID: 38669041; PMCID: PMC12046062.
  16. Latif F, Mubbashir A, Khan MS, Shaikh Z, Memon A, Alvares J, Azhar A, Jain H, Ahmed R, Kanagala SG. Trimethylamine N-oxide in cardiovascular disease: Pathophysiology and the potential role of statins. Life Sci. 2025 Jan 15;361:123304. doi: 10.1016/j.lfs.2024.123304. Epub 2024 Dec 11. PMID: 39672256.
  17. Jarmukhanov Z, Mukhanbetzhanov N, Kozhakhmetov S, Nurgaziyev M, Sailybayeva A, Bekbossynova M, Kushugulova A. The association between the gut microbiota metabolite trimethylamine N-oxide and heart failure. Front Microbiol. 2024 Sep 26;15:1440241. doi: 10.3389/fmicb.2024.1440241. PMID: 39391607; PMCID: PMC11464299.
  18. Yu X, Wang Y, Yang R, Wang Z, Wang X, Wang S, Zhang W, Dong J, Chen W, Ji F, Gao W. Trimethylamine N-oxide predicts cardiovascular events in coronary artery disease patients with diabetes mellitus: a prospective cohort study. Front Endocrinol (Lausanne). 2024 Jul 18;15:1360861. doi: 10.3389/fendo.2024.1360861. PMID: 39092284; PMCID: PMC11291261.
  19. Hou CY, Chen YW, Hazeena SH, Tain YL, Hsieh CW, Chen DQ, Liu RY, Shih MK. Cardiovascular risk of dietary trimethylamine oxide precursors and the therapeutic potential of resveratrol and its derivatives. FEBS Open Bio. 2024 Mar;14(3):358-379. doi: 10.1002/2211-5463.13762. Epub 2024 Jan 21. PMID: 38151750; PMCID: PMC10909991.
  20. Sun Y, Lin X, Liu Z, Hu L, Sun P, Shen G, Fan F, Zhang Y, Li J. Association between plasma trimethylamine N-oxide and coronary heart disease: new insights on sex and age differences. Front Cardiovasc Med. 2024 Oct 7;11:1397023. doi: 10.3389/fcvm.2024.1397023. PMID: 39434851; PMCID: PMC11491342.
  21. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013 Apr 25;368(17):1575-84. doi: 10.1056/NEJMoa1109400. PMID: 23614584; PMCID: PMC3701945.
  22. Senthong V, Wang Z, Li XS, Fan Y, Wu Y, Tang WH, Hazen SL. Intestinal Microbiota-Generated Metabolite Trimethylamine-N-Oxide and 5-Year Mortality Risk in Stable Coronary Artery Disease: The Contributory Role of Intestinal Microbiota in a COURAGE-Like Patient Cohort. J Am Heart Assoc. 2016 Jun 10;5(6):e002816. doi: 10.1161/JAHA.115.002816. PMID: 27287696; PMCID: PMC4937244.
  23. Cardona A, O'Brien A, Bernier MC, Somogyi A, Wysocki VH, Smart S, He X, Ambrosio G, Hsueh WA, Raman SV. Trimethylamine N-oxide and incident atherosclerotic events in high-risk individuals with diabetes: an ACCORD trial post hoc analysis. BMJ Open Diabetes Res Care. 2019 Nov 15;7(1):e000718. doi: 10.1136/bmjdrc-2019-000718. PMID: 31798892; PMCID: PMC6861061.
  24. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WH, Bushman FD, Lusis AJ, Hazen SL. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013 May;19(5):576-85. doi: 10.1038/nm.3145. Epub 2013 Apr 7. PMID: 23563705; PMCID: PMC3650111.
  25. Cho CE, Caudill MA. Trimethylamine-N-Oxide: Friend, Foe, or Simply Caught in the Cross-Fire? Trends Endocrinol Metab. 2017 Feb;28(2):121-130. doi: 10.1016/j.tem.2016.10.005. Epub 2016 Nov 5. PMID: 27825547.
  26. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011 Apr 7;472(7341):57-63. doi: 10.1038/nature09922. PMID: 21475195; PMCID: PMC3086762.
  27. Velasquez MT, Ramezani A, Manal A, Raj DS. Trimethylamine N-Oxide: The Good, the Bad and the Unknown. Toxins (Basel). 2016 Nov 8;8(11):326. doi: 10.3390/toxins8110326. PMID: 27834801; PMCID: PMC5127123.
  28. Mulijono D, Hutapea AM, Lister INE, Sudaryo MK, Umniyati H. Mechanisms of plant-based diets reverse atherosclerosis. Cardiology and Cardiovascular Medicine. 2024;8(4):290-302. doi: 10.26502/fccm.92920390.
  29. Mulijono D. Plant-Based diet in regressing/stabilizing vulnerable plaques to achieve complete revascularization. Archives of Clinical and Biomedical Research. 2024;8(3):236-244. doi: 10.26502/acbr.50170405.
  30. Mulijono D, Hutapea AM, Lister INE, Sudaryo MK, Umniyati H. How a Plant-Based Diet (PBD) Reduces In-Stent Restenosis (ISR) and Stent Thrombosis (ST). Cardio Open. 2024;9(1):01-15. doi: 10.33140/COA.09.01.05.
  31. Mulijono D, Hutapea AM, Lister INE, Sudaryo MK, and Umniyati H. Plant-Based diet to reverse/ regress vulnerable plaque: A case report and review. Archives of Clinical and Medical Case Reports. 2024;8(3):126-135. doi: 10.26502/acmcr.96550674.
  32. Mulijono D. Bethsaida hospital: Pioneering plant-based diet and lifestyle medicine revolution in Indonesia. Arch Epidemiol Pub Health Res. 2025;4(1):01-03. doi: 10.33140/AEPHR.04.01.02.
  33. Mulijono D. Prof. Dasaad Mulijono: The plant-based guru redefining cardiology and preventive medicine. On J Cardio Res & Rep. 2025;8(1). doi: 10.33552/OJCRR.2025.08.000676.
  34. Mulijono D. Healing with food or managing with injection? A new era in chronic disease care. J Biomed Res Environ Sci. 2025;6(4):373-377. doi: 10.37871/jbres2092.
  35. Mulijono D. How a plant-based diet and ultra-low ldl levels can reverse atherosclerosis and prevent restenosis: A breakthrough in heart health. J Biomed Res Environ Sci. 2025;6(4):368-372. doi: 10.37871/jbres2091.
  36. Mulijono D. Reclaiming healing through nutrition: Resistance to plant-based diets and the biblical call to restoration. Arch Epidemiol Pub Health Res. 2025;4(2):01-03. doi: 10.33140/AEPHR.04.02.01.
  37. Mulijono D. What was meant for harm. A testimony of healing, faith, and medical revolution. Arch Epidemiol Pub Health Res. 2025;4(2):01-05. doi: 10.33140/AEPHR.
  38. Gatarek P, Kaluzna-Czaplinska J. Trimethylamine N-oxide (TMAO) in human health. EXCLI J. 2021 Feb 11;20:301-319. doi: 10.17179/excli2020-3239. PMID: 33746664; PMCID: PMC7975634.
  39. Jaworska K, Kopacz W, Koper M, Ufnal M. Microbiome-Derived Trimethylamine N-Oxide (TMAO) as a Multifaceted Biomarker in Cardiovascular Disease: Challenges and Opportunities. Int J Mol Sci. 2024 Nov 21;25(23):12511. doi: 10.3390/ijms252312511. PMID: 39684223; PMCID: PMC11641139.
  40. Liu J, Ge P, Luo Y, Sun Z, Luo X, Li H, Pei B, Xun L, Zhang X, Jiang Y, Wen H, Liu J, Yang Q, Ma S, Chen H. Decoding TMAO in the Gut-Organ Axis: From Biomarkers and Cell Death Mechanisms to Therapeutic Horizons. Drug Des Devel Ther. 2025 Apr 29;19:3363-3393. doi: 10.2147/DDDT.S512207. PMID: 40322030; PMCID: PMC12049683.
  41. Caradonna E, Abate F, Schiano E, Paparella F, Ferrara F, Vanoli E, Difruscolo R, Goffredo VM, Amato B, Setacci C, Setacci F, Novellino E. Trimethylamine-N-Oxide (TMAO) as a Rising-Star Metabolite: Implications for Human Health. Metabolites. 2025 Mar 24;15(4):220. doi: 10.3390/metabo15040220. PMID: 40278349; PMCID: PMC12029716.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership